Following a legal victory over Abbott Laboratories, Cambridge Antibody Technology (CAT) will now receive royalties on the rheumatoid arthritis therapeutic Humira#174; (adalimumab), at a rate more than double the one it was receiving before. This feature considers the significance of the court's verdict both to CAT and the wider biotechnology industry.